臨床腫瘍学次世代シーケンスの世界市場レポート 2025年

臨床腫瘍学次世代シーケンスの市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.9％で9億5,000万米ドルに成長します。予測期間の成長は、がん罹患率の増加、精密医療、免疫腫瘍学、リキッドバイオプシーに起因しています。予測期間の主な動向には、包括的ゲノムプロファイリング（CGP）、免疫腫瘍学、腫瘍の進化と不均一性、AI、機械学習が含まれます。

世界のがん患者数の増加が、当面の臨床腫瘍学次世代シーケンサー市場の成長要因になると予想されます。米国がん協会のデータによると、2021年には米国だけで190万人の新規がん患者と60万人のがん関連死亡者が報告されました。世界的に最も多いがん種は、肺がん、前立腺がん、大腸がん、乳がんで、新規がん患者全体の43％を占めています。その結果、世界のがん罹患率の上昇が需要を促進し、臨床腫瘍学次世代シーケンス市場の成長を促進すると考えられます。

がんの有病率の上昇は、臨床腫瘍学次世代シーケンサー（NGS）市場の成長を促進すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする疾患群を指します。NGSは、がんにおける新規変異や希少変異の検出において重要な役割を果たし、個々の腫瘍の分子基盤の理解を深めるのに役立っています。例えば、2024年5月、米国の政府機関である国立がん研究所は、米国におけるがん生存者数は約1,810万人であると報告しました。この数は2032年までに2,250万人に増加すると予測されています。2040年には、年間新規がん患者数は2,990万人に達し、がんに関連した死亡者数は1,530万人になると推定されています。したがって、がんの有病率の増加は、臨床腫瘍学次世代シーケンス市場の拡大を促進する主要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の臨床腫瘍学次世代シーケンス市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の臨床腫瘍学次世代シーケンス市場：成長率分析
• 世界の臨床腫瘍学次世代シーケンス市場の実績：規模と成長、2019～2024年
• 世界の臨床腫瘍学次世代シーケンス市場の予測：規模と成長、2024～2029年、2034年
• 世界の臨床腫瘍学次世代シーケンス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の臨床腫瘍学次世代シーケンス市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• イオン半導体シーケンス
• ピロシーケンス
• 合成シーケンス
• リアルタイムシーケンス
• ライゲーションシーケンス
• 可逆的色素終結シーケンス
• ナノポアシーケンス
• 世界の臨床腫瘍学次世代シーケンス市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• スクリーニング
• コンパニオン診断
• その他
• 世界の臨床腫瘍学次世代シーケンス市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院検査室
• 臨床研究機関
• 診断検査室
• 世界の臨床腫瘍学次世代シーケンス市場：イオン半導体シーケンスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• イオンプロトンシステム
• イオンPGMシステム
• イオンS5システム
• その他
• 世界の臨床腫瘍学次世代シーケンス市場：ピロシーケンスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 454ピロシーケンス
• その他
• 世界の臨床腫瘍学次世代シーケンス市場：合成シーケンスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• Illuminaシーケンス技術
• SOLiDシーケンス技術
• その他
• 世界の臨床腫瘍学次世代シーケンス市場：リアルタイムシーケンスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• PacBio RS IIシステム
• Sequelシステム
• その他
• 世界の臨床腫瘍学次世代シーケンス市場：ライゲーションシーケンスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ヘリコシングル分子シーケンス
• その他
• 世界の臨床腫瘍学次世代シーケンス市場：可逆的色素終結シーケンスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• Illumina HiSeq
• Illumina NextSeq
• その他
• 世界の臨床腫瘍学次世代シーケンス市場：ナノポアシーケンスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• Oxford Nanopore技術（MinION、GridION、PromethION）
• その他

第7章 地域別・国別分析

• 世界の臨床腫瘍学次世代シーケンス市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の臨床腫瘍学次世代シーケンス市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 臨床腫瘍学次世代シーケンス市場：競合情勢
• 臨床腫瘍学次世代シーケンス市場：企業プロファイル
  • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• F. Hoffmann-La Roche Ltd.
• PerkinElmer Inc.
• Agilent Technologies Inc.
• Pacific Biosciences of California Inc.
• Caris Life Sciences
• Paradigm Diagnostics
• GATC Biotech AG
• Macrogen Inc.
• DNASTAR Inc.
• Exosome Diagnostics Inc.
• Biomatters Ltd.
• Partek Inc.
• Foundation Medicine Inc.
• Becton Dickinson and Company（BD）
• Takara Bio Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 臨床腫瘍学次世代シーケンス市場2029：新たな機会を提供する国
• 臨床腫瘍学次世代シーケンス市場2029：新たな機会を提供するセグメント
• 臨床腫瘍学次世代シーケンス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

The increasing number of cancer cases worldwide is expected to be a contributing factor to the growth of the clinical oncology next-generation sequencing market in the foreseeable future. In 2021, the USA alone reported 1.9 million new cancer cases and 0.6 million cancer-related deaths, according to data from the American Cancer Society. The most common cancer types globally include lung, prostate, colorectal, and breast cancer, accounting for 43% of all new cancer cases. Consequently, the rising global incidence of cancer is likely to drive demand and foster growth in the clinical oncology next-generation sequencing market.

The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.

Companies in the clinical oncology next-generation sequencing market are increasingly investing in workflow automation to enhance precision and reduce sample-to-sample variability. For example, Agilent automation solutions have developed an automated system that enables a higher number of parallel reactions, reduces sample processing time, increases the volume of processed samples, and minimizes variability between samples. Additionally, companies like Sophia Genetics are focusing on data-driven medicine and the automation of DNA sequencing to enhance diagnostic and treatment capabilities.

Major companies operating in the clinical oncology next-generation sequencing market are introducing innovative products like the BenchMark ULTRA PLUS system to enhance their market competitiveness. The BenchMark ULTRA PLUS System is a valuable tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it ensures the accuracy and efficiency of diagnostic tests, ultimately contributing to improved patient care. For example, in June 2022, the Switzerland-based pharmaceutical company Roche unveiled the BenchMark ULTRA PLUS system, their state-of-the-art platform for tissue staining. This system provides clinicians with rapid and accurate test results, aiding in timely treatment decisions for patients.

In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Oncology Next Generation Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The clinical oncology next generation sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
• 2) By Application: Screening; Companion Diagnostics; Other Diagnostics
• 3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
• Subsegments:
• 1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies
• 2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
• 3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
• 4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
• 5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
• 6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
• 7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
• Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies

4. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Clinical Oncology Next Generation Sequencing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Clinical Oncology Next Generation Sequencing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Clinical Oncology Next Generation Sequencing Market Growth Rate Analysis
• 5.4. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM)

6. Clinical Oncology Next Generation Sequencing Market Segmentation

• 6.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing
• Real Time Sequencing
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano-Pore Sequencing
• 6.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Screening
• Companion Diagnostics
• Other Diagnostics
• 6.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic Laboratories
• 6.4. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ion Semiconductor Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ion Proton System
• Ion PGM System
• Ion S5 System
• Other Ion Semiconductor Sequencing Technologies
• 6.5. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Pyro-Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 454 Pyrosequencing
• Other Pyro-Sequencing Technologies
• 6.6. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Synthesis Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Illumina Sequencing Technology
• SOLiD Sequencing Technology
• Other Synthesis Sequencing Technologies
• 6.7. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Real-Time Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PacBio RS II System
• Sequel System
• Other Real-Time Sequencing Technologies
• 6.8. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ligation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Helicos Single Molecule Sequencing
• Other Ligation Sequencing Technologies
• 6.9. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Reversible Dye Termination Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Illumina HiSeq
• Illumina NextSeq
• Other Reversible Dye Termination Sequencing Technologies
• 6.10. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Nano-Pore Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oxford Nanopore Technologies (MinION, GridION, PromethION)
• Other Nano-Pore Sequencing Technologies

7. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

• 7.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

• 8.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Clinical Oncology Next Generation Sequencing Market

• 9.1. China Clinical Oncology Next Generation Sequencing Market Overview
• 9.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Clinical Oncology Next Generation Sequencing Market

• 10.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Clinical Oncology Next Generation Sequencing Market

• 11.1. Japan Clinical Oncology Next Generation Sequencing Market Overview
• 11.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Clinical Oncology Next Generation Sequencing Market

• 12.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Clinical Oncology Next Generation Sequencing Market

• 13.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Clinical Oncology Next Generation Sequencing Market

• 14.1. South Korea Clinical Oncology Next Generation Sequencing Market Overview
• 14.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Clinical Oncology Next Generation Sequencing Market

• 15.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
• 15.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Clinical Oncology Next Generation Sequencing Market

• 16.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Clinical Oncology Next Generation Sequencing Market

• 17.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Clinical Oncology Next Generation Sequencing Market

• 18.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Clinical Oncology Next Generation Sequencing Market

• 19.1. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Clinical Oncology Next Generation Sequencing Market

• 20.1. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Clinical Oncology Next Generation Sequencing Market

• 21.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
• 21.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Clinical Oncology Next Generation Sequencing Market

• 22.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Clinical Oncology Next Generation Sequencing Market

• 23.1. North America Clinical Oncology Next Generation Sequencing Market Overview
• 23.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Clinical Oncology Next Generation Sequencing Market

• 24.1. USA Clinical Oncology Next Generation Sequencing Market Overview
• 24.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Clinical Oncology Next Generation Sequencing Market

• 25.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
• 25.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Clinical Oncology Next Generation Sequencing Market

• 26.1. South America Clinical Oncology Next Generation Sequencing Market Overview
• 26.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Clinical Oncology Next Generation Sequencing Market

• 27.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Clinical Oncology Next Generation Sequencing Market

• 28.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
• 28.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Clinical Oncology Next Generation Sequencing Market

• 29.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
• 29.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

• 30.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape
• 30.2. Clinical Oncology Next Generation Sequencing Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Clinical Oncology Next Generation Sequencing Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche Ltd.
• 31.2. PerkinElmer Inc.
• 31.3. Agilent Technologies Inc.
• 31.4. Pacific Biosciences of California Inc.
• 31.5. Caris Life Sciences
• 31.6. Paradigm Diagnostics
• 31.7. GATC Biotech AG
• 31.8. Macrogen Inc.
• 31.9. DNASTAR Inc.
• 31.10. Exosome Diagnostics Inc.
• 31.11. Biomatters Ltd.
• 31.12. Partek Inc.
• 31.13. Foundation Medicine Inc.
• 31.14. Becton Dickinson and Company (BD)
• 31.15. Takara Bio Inc.

32. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

34. Recent Developments In The Clinical Oncology Next Generation Sequencing Market

35. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies

• 35.1 Clinical Oncology Next Generation Sequencing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Clinical Oncology Next Generation Sequencing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Clinical Oncology Next Generation Sequencing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer